Skip to main content
Lunai Bioworks Inc. logo

Lunai Bioworks Inc. — Investor Relations & Filings

Ticker · RENB ISIN · US29350E1047 US Professional, scientific and technical activities
Open in API
Filings indexed 580 across all filing types
Latest filing 2023-01-05 Director's Dealing
Country US United States of America
Listing US RENB

About Lunai Bioworks Inc.

https://www.lunaibio.com

Lunai Bioworks Inc. is a pre-clinical stage biotechnology company that utilizes artificial intelligence for drug discovery and biodefense. The company focuses on pioneering safe and responsible generative biology to develop new therapies. By harnessing phenomics and AI, it aims to decode disease signals and translate them into treatments. Its proprietary Transformer Platform is designed to accelerate drug discovery processes. Lunai Bioworks develops medicines, diagnostics, and biodefense products, with a pipeline that includes programs for neurodegenerative conditions like Alzheimer's disease.

Recent filings

Filing Released Lang Actions
Director's Dealing 2023
Director's Dealing
2023-01-05 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text specifically discusses a Nasdaq notification regarding the company's plan to regain compliance with Nasdaq Listing Rule 5250(c)(1). It mentions the requirement to file the Annual Report on Form 10-K and Quarterly Report on Form 10-Q by certain dates but does not contain the reports themselves or detailed financial data. The document is short (3317 characters) and serves as an announcement of an event related to regulatory compliance and Nasdaq listing status. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2022-12-30 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. The content focuses on changes in senior management and amendments to employment agreements, including salary adjustments and equity grants for executives. There are no financial statements or detailed financial performance data presented. The primary subject is the appointment of a new Chief Operating Officer, salary changes for executives, and related compensatory arrangements. This fits the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management. The document is not an annual or quarterly report, audit report, earnings release, or any other category. Therefore, the correct classification is MANG with high confidence.
2022-12-16 English
FORM 8-K
Delisting Announcement Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to disclose significant events. The content specifically discusses a notice from Nasdaq regarding the company's failure to timely file its Quarterly Report on Form 10-Q and Annual Report on Form 10-K, leading to non-compliance with Nasdaq listing rules and a potential delisting. The document includes a press release about this notice and details about the compliance timeline and possible consequences. This is a regulatory announcement about the company's listing status and compliance issues, not the actual financial reports or audit reports themselves. The primary subject is the notice of potential delisting due to non-compliance with filing requirements. Therefore, the most appropriate classification is a Delisting Announcement (DLST). The document length is over 5,000 characters and contains substantive information about the delisting notice, not just a brief announcement or certification, supporting this classification.
2022-11-30 English
FORM NT 10-Q
Regulatory Filings Classification · 100% confidence The document is a Form 12b-25, which is a Notification of Late Filing submitted to the SEC. It specifically states that the company, Enochian Biosciences Inc., could not file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, on time due to delays in obtaining third-party valuation information. The document does not contain the actual 10-Q report or substantive financial data but is a notification explaining the delay and requesting relief under Rule 12b-25. According to the classification rules, such a notification is a regulatory filing and not the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-11-15 English
Director's Dealing 2022
Director's Dealing
2022-10-27 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.